TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Essex Bio-Technology ( (HK:1061) ) has shared an announcement.
Essex Bio-Technology Limited has received approval from the National Medical Products Administration for the commercialization of its multi-dose Diquafosol Sodium Eye Drops in the People’s Republic of China. This product, aimed at treating dry eye syndromes, expands the company’s ophthalmic treatment options in the region, potentially strengthening its market position and offering more choices to patients.
More about Essex Bio-Technology
Essex Bio-Technology Limited operates in the biotechnology industry, focusing on the development and commercialization of biopharmaceutical products. The company primarily offers treatments for ophthalmic diseases and conditions, with a market focus on the People’s Republic of China.
Average Trading Volume: 1,597,517
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.95B
See more data about 1061 stock on TipRanks’ Stock Analysis page.